EcoDrugPlus

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSDNOG00000012801
Gene Symbol: HTR3B
2 Cross references
175 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSDNOG00000015980
Gene Symbol: HTR4
2 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSDNOG00000041894
Gene Symbol: HTR5A
4 Cross references
216 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSDNOG00000042643
Gene Symbol: HTR6
2 Cross references
115 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSDNOG00000024730
Gene Symbol: HTR7
2 Cross references
221 Possible Orthologues:

60s Ribosomal Protein L19

Ensembl ID : ENSDNOG00000024769
Gene Symbol: LOC101446894
3 Cross references
243 Possible Orthologues:

60s Ribosomal Protein L23-Like

Ensembl ID : ENSDNOG00000033557
Gene Symbol: LOC101437018
3 Cross references
146 Possible Orthologues:

60s Ribosomal Protein L26-Like

Ensembl ID : ENSDNOG00000002289
Gene Symbol: LOC101439196
3 Cross references
132 Possible Orthologues:

60s Ribosomal Protein L27a

Ensembl ID : ENSDNOG00000041820
Gene Symbol: LOC101410771
3 Cross references
264 Possible Orthologues:

60s Ribosomal Protein L27a

Ensembl ID : ENSDNOG00000033454
Gene Symbol: LOC101436039
3 Cross references
264 Possible Orthologues:

60s Ribosomal Protein L28

Ensembl ID : ENSDNOG00000044172
Gene Symbol: LOC101426422
3 Cross references
217 Possible Orthologues:

60s Ribosomal Protein L30-Like

Ensembl ID : ENSDNOG00000041593
Gene Symbol: LOC101441097
3 Cross references
214 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).